Within the seven major markets, 12% to 20% of diagnosed prevalent NASH cases present severe liver damage (stage 4 liver fibrosis), denoting cirrhosis.
Diagnosed prevalent cases of NASH to reach 26.55 million
Go to source) The report ’Non-Alcoholic Steatohepatitis (NASH/MASH): Epidemiology Forecast to 2032’ predicts the US to have the highest NASH cases in 2032 at 10.45 million, while Spain is estimated to have the lowest at 1.15 million within the 7MM.
What is NAFLD?
Non-alcoholic steatohepatitis (NASH), also known as non-alcoholic fatty liver disease (NAFLD), represents a progressive liver condition characterized by the accumulation of fat in the liver, inflammation, and liver cell damage. This condition can advance to more severe stages, leading to fibrosis, cirrhosis, and even liver failure in some cases.
Renaming ‘Fatty Liver or NAFLD to ‘MAFLD’
Global liver societies have renamed Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD).
Global liver societies have renamed Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD).
‘The 5EU (France, Germany, Italy, Spain, and the UK) is expected to account for 11.77 million diagnosed prevalent cases of NASH by 2032. #hepatitis #fattyliverdisease #MAFLD #NASH ’
Metabolic-associated fatty liver disease (MAFLD), formerly known as alcoholic fatty liver disease, encompasses a broader spectrum of liver conditions linked to metabolic dysfunction, encompassing similar characteristics as NASH. Both NASH and MAFLD are strongly associated with obesity, insulin resistance, type 2 diabetes, and other metabolic factors, making them prevalent concerns in the context of modern lifestyles. Casey Freimuth, Senior Epidemiologist at GlobalData, emphasizes the need to monitor trends in NAFLD, obesity, and type 2 diabetes for predicting NASH’s future burden. Surveillance of risk factors like waist circumference, body mass index, triglycerides, and gamma-glutamyl Transferase levels is deemed vital in assessing NASH risk within populations.
Early NASH diagnosis becomes critical, as cirrhosis lacks a curative treatment. Effective management targeting obesity and insulin resistance, the underlying causes, is pivotal in preventing liver failure.
Fatty Liver Disease: A Growing Health Problem in India
Non alcoholic fatty liver disease (NAFLD) is the leading cause of liver dysfunction worldwide and is a rapidly growing health problem in India.
Non alcoholic fatty liver disease (NAFLD) is the leading cause of liver dysfunction worldwide and is a rapidly growing health problem in India.
- Diagnosed prevalent cases of NASH to reach 26.55 million - (https://www.globaldata.com/media/pharma/diagnosed-prevalent-cases-nash-reach-26-55-million-7mm-2032-estimates-globaldata/)
Test Your Knowledge on Liver Cancer
Primary hepatocellular carcinoma is a cancer that starts in the liver. The liver is the largest organ in the body situated in the upper right quadrant of the abdomen. The liver is also a common site for cancer deposits (metastases) from other ...
Primary hepatocellular carcinoma is a cancer that starts in the liver. The liver is the largest organ in the body situated in the upper right quadrant of the abdomen. The liver is also a common site for cancer deposits (metastases) from other ...
Breakthrough Cell Therapy for Cirrhosis, an Advanced Liver Disease
Researchers have devised a novel approach that harnesses the patient's own cells to aid in the treatment of liver cirrhosis.
Researchers have devised a novel approach that harnesses the patient's own cells to aid in the treatment of liver cirrhosis.
